Enanta Pharmaceuticals Net Worth
Enanta Pharmaceuticals Net Worth Breakdown | ENTA |
Enanta Pharmaceuticals Net Worth Analysis
Enanta Pharmaceuticals' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Enanta Pharmaceuticals' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Enanta Pharmaceuticals' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Enanta Pharmaceuticals' net worth analysis. One common approach is to calculate Enanta Pharmaceuticals' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Enanta Pharmaceuticals' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Enanta Pharmaceuticals' net worth. This approach calculates the present value of Enanta Pharmaceuticals' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Enanta Pharmaceuticals' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Enanta Pharmaceuticals' net worth. This involves comparing Enanta Pharmaceuticals' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Enanta Pharmaceuticals' net worth relative to its peers.
Enterprise Value |
|
To determine if Enanta Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Enanta Pharmaceuticals' net worth research are outlined below:
| Enanta Pharmaceuticals had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 67.64 M. Net Loss for the year was (116.05 M) with profit before overhead, payroll, taxes, and interest of 66.59 M. | |
| Enanta Pharmaceuticals currently holds about 253.29 M in cash with (78.76 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 96.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: Enanta Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune Inflammatory Disease Virtual Conference |
Enanta Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Enanta Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Enanta Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 6th of February 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 18th of November 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 30th of September 2023 Last Financial Announcement | View |
Know Enanta Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Enanta Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Enanta Pharmaceuticals backward and forwards among themselves. Enanta Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Enanta Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | D. E. Shaw & Co Lp | 2024-12-31 | 421.6 K | Northern Trust Corp | 2024-12-31 | 387.4 K | Stonepine Capital Management Llc | 2024-12-31 | 331.9 K | Dimensional Fund Advisors, Inc. | 2024-12-31 | 297.1 K | Jacobs Levy Equity Management, Inc. | 2024-12-31 | 290 K | Assenagon Asset Management Sa | 2024-12-31 | 192.9 K | Caligan Partners Lp | 2024-12-31 | 184.8 K | Sio Capital Management, Llc | 2024-12-31 | 177 K | Jpmorgan Chase & Co | 2024-12-31 | 163.1 K | Krensavage Asset Management, Llc | 2024-12-31 | 2.1 M | Farallon Capital Management, L.l.c. | 2024-12-31 | 2.1 M |
Follow Enanta Pharmaceuticals' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 134.61 M.Market Cap |
|
Project Enanta Pharmaceuticals' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.35) | (0.34) | |
| Return On Capital Employed | (0.44) | (0.42) | |
| Return On Assets | (0.35) | (0.34) | |
| Return On Equity | (1.04) | (0.98) |
When accessing Enanta Pharmaceuticals' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Enanta Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Enanta Pharmaceuticals' profitability and make more informed investment decisions.
Please note, the presentation of Enanta Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Enanta Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Enanta Pharmaceuticals' management manipulating its earnings.
Evaluate Enanta Pharmaceuticals' management efficiency
Enanta Pharmaceuticals has return on total asset (ROA) of (0.1775) % which means that it has lost $0.1775 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.691) %, meaning that it created substantial loss on money invested by shareholders. Enanta Pharmaceuticals' management efficiency ratios could be used to measure how well Enanta Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.34. The current year's Return On Capital Employed is expected to grow to -0.42. At present, Enanta Pharmaceuticals' Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Other Assets is expected to grow to about 5.6 M, whereas Total Assets are forecasted to decline to about 333.8 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 5.48 | 5.91 | |
| Tangible Book Value Per Share | 5.48 | 5.93 | |
| Enterprise Value Over EBITDA | (2.61) | (2.48) | |
| Price Book Value Ratio | 1.53 | 1.88 | |
| Enterprise Value Multiple | (2.61) | (2.48) | |
| Price Fair Value | 1.53 | 1.88 | |
| Enterprise Value | 193.9 M | 203.6 M |
Understanding the operational decisions made by Enanta Pharmaceuticals management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Enterprise Value Revenue 0.8326 | Revenue | Quarterly Revenue Growth (0.06) | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Enanta Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Enanta Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Enanta Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Enanta Pharmaceuticals Corporate Filings
8K | 17th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 14th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10Q | 12th of February 2025 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
| 11th of February 2025 Other Reports | ViewVerify |
Enanta Pharmaceuticals Earnings per Share Projection vs Actual
Enanta Pharmaceuticals Corporate Management
| Nathaniel JD | General VP | Profile | |
| Scott MD | Senior Officer | Profile | |
| Nathalie MD | Consultant | Profile | |
| Jennifer Viera | Executive Communications | Profile | |
| Tara Kieffer | Senior Development | Profile | |
| Brendan Luu | Senior Development | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enanta Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Enanta Stock refer to our How to Trade Enanta Stock guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enanta Pharmaceuticals. If investors know Enanta will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enanta Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.66) | Earnings Share (4.95) | Revenue Per Share | Quarterly Revenue Growth (0.06) | Return On Assets |
The market value of Enanta Pharmaceuticals is measured differently than its book value, which is the value of Enanta that is recorded on the company's balance sheet. Investors also form their own opinion of Enanta Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Enanta Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enanta Pharmaceuticals' market value can be influenced by many factors that don't directly affect Enanta Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enanta Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enanta Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enanta Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.